The 80 patient phase 3 study of lonvoguran ziclumeran, an in body (in vivo) CRISPR therapy that permanently disables the KLKB1 gene (the liver gene whose runaway protein drives hereditary angioedema swelling), is the first such readout in humans.
For the roughly 1 in 50,000 people born with hereditary angioedema (HAE), a rare inherited condition that drives sudden, unpredictable swelling of the face, limbs, gut, and airways and can become life-threatening, the standard of care means choosing between near-daily preventive shots or infusions and fast-acting rescue medication. Intellia Therapeutics is reporting phase 3 results it says could make that recurring regimen a thing of the past.
Intellia said on June 13 that its one-time gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met both primary and secondary endpoints in the Haelo trial with statistical and clinical significance, hitting its main goal roughly six weeks ahead of schedule. Lonvo-z is an in vivo CRISPR therapy: an infusion delivers editing machinery to the liver, where it permanently disables the KLKB1 gene, lowering the kallikrein protein whose excess form, bradykinin, drives HAE swelling.
In the 80-patient, randomized, placebo-controlled Haelo study (52 lonvo-z, 28 placebo), patients on lonvo-z saw an 87% mean reduction in monthly HAE attacks over weeks 5 to 28 compared with placebo (p<0.0001). Sixty-two percent of patients on the gene-editing therapy were attack-free and treatment-free across the six-month efficacy window, versus 11% on placebo (p<0.0001). Secondary endpoints told a similar story: lonvo-z patients had an 89% reduction in the monthly rate of attacks requiring on-demand rescue treatment and a 91% reduction in moderate-to-severe attacks over the same period (both p<0.0001). Patients on lonvo-z also reported a 17-point improvement in the AE-QoL quality-of-life measure by week 28, against a 6-point threshold typically used to define clinical meaningfulness (p<0.0001).
These are the first phase 3 results for an in vivo CRISPR gene-editing therapy in humans. "These are the first Phase 3 results to deliver on the much-heralded promise of in vivo CRISPR gene editing," Intellia CEO John Leonard, M.D., said in the company's June 13 release. A Jefferies analyst note, independently cross-checked, characterized lonvo-z as "paradigm-shifting." Intellia shares rose on the news Monday morning following the June 13 release, per the Fierce Biotech summary of the day.
The framing is worth holding to evidence. "Paradigm-shifting" and "one-time treatment" are company and analyst language, and the data cover six months. Plasma kallikrein levels decreased substantially by day 15, reached steady state by week 5, and remained stable through the February 10, 2026 data cutoff — a median follow-up window consistent with the six-month efficacy period. HAE is a lifelong condition, so durability past week 28 remains an open question, as does the lifetime safety of permanently disabling a gene in liver cells. The trial randomized 80 patients, a small number even for a rare disease, and a one-time biology is not the same as a one-time visit: the regimen is an infusion with monitoring, and the company's earlier in vivo work used steroid premedication to manage infusion reactions. All reported treatment-emergent adverse events in the lonvo-z arm were mild or moderate; no serious adverse events were observed in the active arm.
The HAE treatment landscape already includes Ionis Pharmaceuticals' Dawnzera (FDA-approved last year, demonstrating an 81% attack reduction vs. placebo), Takeda's blockbuster prophylactic Takhzyro, and BioCryst Pharmaceuticals' Orladeyo. All require chronic administration. Lonvo-z's key differentiator is its one-time design — if durability holds, it could shift the treatment calculus for patients and prescribers. A rolling BLA submission is underway with FDA; Intellia anticipates regulatory approval and a U.S. launch in the first half of 2027.
What the data do establish is that an in vivo CRISPR therapy can produce a large, durable clinical effect over six months in a controlled trial. What they do not yet establish is whether that effect holds for years, whether rare off-target edits in the liver accumulate problems over a lifetime, or how regulators will weigh a single-dose gene edit against chronic biologics. The Haelo readout answers a real patient question, and leaves the longer one open.